Table 1 The characteristics of patients associated with this study
Author | Country | Study design | Year | Case | M/F | Mean age (range) (years) | Mean symptoms duration (range) (months) | Prior treatment n(%) | Mean follow-up (range) (months) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EBD | BTI | LHM | Others | Overall | |||||||||
Hu et al. [12] | China | Prospective | 2015 | 32 | 17/15 | 43.6 (18.0~72.0) | 40.8 (1.2~600.0) | 14 (43.8) | 3 (9.4) | 3 (9.4) | 3 (9.4) | 23 (71.9) | 30.0 (24.0~44.0) |
Peng et al. [13] | China | Retrospective | 2017 | 13 | 8/5 | 37.5 ± 13.0 | 46.8 ± 33.6 | 3 (23.1) | 0 (0) | 0 (0) | 3 (23.1) | 6 (46.2) | 46.2 ± 4.1 |
Zhang et al. [14] | China | Retrospective | 2017 | 32 | 16/16 | 43.3 (16.0~79.0) | 24.0 (2.4~336.0) | 0 (0) | 1 (3.1) | 0 (0) | 0 (0) | 1 (3.1) | 27.0 (24.0~51.0) |
Chen et al. [15] | China | Prospective | 2015 | 27 | 11/16 | 13.8 (6.0~17.0) | 20.4 (2.4~36.0) | 5 (18.5) | 1 (3.7) | 0 (0) | 9 (33.3) | 15 (55.6) | 24.6 (15.0~38.0) |
Lv et al. [16] | China | Retrospective | 2016 | 6 | 1/5 | 49.0 (21.0~72.0) | 96.0 (24.0~300.0) | 0 (0) | 0 (0) | 0 (0) | 2 (33.3) | 2 (33.3) | 34.5 (median) |
Zhang et al. [17] | China | Retrospective | 2017 | 21 | 9/12 | 38.0 (15.0~64.0) | 26.0 (10.0~360.0) | 0 (0) | 3 (14.3) | 0 (0) | 1 (4.8) | 4 (19.1) | 42.0 (9.0~62.0) |
Meng et al. [18] | China | Retrospective | 2017 | 32 | 13/19 | 44.8 ± 11.6 | 24.0 (12.0~60.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 25.0 ± 11.0 |
Duan et al. [19] | China | Retrospective | 2017 | 123 | 63/60 | 42.1 (14.0~74.0) | 60.0 (6.0~396.0) | 11 | 4 | 0 (0) | 3 | 18 | 30.0 (24.0~46.0) |
Teitelbaum et al. [20] | USA | Prospective | 2017 | 36 | 16/20 | 55.0 (20.0~88.0) | NR | NR | NR | 0 (0) | 18 (50.0) | 18 (50.0) | 65.0 (median) |
Amy Tyberg et al. [21] | USA | Prospective | 2017 | 51 | 24/27 | 54.2 | 134.4 | 0 (0) | 0 (0) | 43 (84.0) | NR | 45 (88.0) | 24.4 (12.0~52.0) |
Total | 373 | 178/195 | 42.1 | 52.5 | 33 (8.8) | 12 (3.2) | 46 (12.3) | 39 (10.5) | 132 (35.4) | 30.0 | |||